Anixa Biosciences (NASDAQ:ANIX) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Anixa Biosciences from a "sell" to a "hold," while D. Boral Capital reiterated a "buy" with a $10.00 price target; the consensus rating is currently "Hold" with a consensus price target of $8.50.
• Shares were trading up about 4.7%, opening at $3.14 with a market cap of roughly $105.3 million, a negative P/E (-9.51), and a 12‑month range of $2.44 to $5.46 (50‑day/200‑day averages $2.83/$3.41).
• Anixa is a clinical‑stage immuno‑oncology and infectious disease company advancing an ovarian cancer immunotherapy, a COVID‑19 vaccine using VLP technology, and the ADAPT high‑throughput proteomics diagnostic platform.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

Separately, D. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Wednesday, April 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $8.50.

Anixa Biosciences Trading Up 4.7%

NASDAQ:ANIX opened at $3.14 on Friday. The company's 50-day moving average price is $2.83 and its 200-day moving average price is $3.41. The company has a market cap of $105.28 million, a P/E ratio of -9.51 and a beta of 0.64. Anixa Biosciences has a twelve month low of $2.44 and a twelve month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. On average, analysts expect that Anixa Biosciences will post -0.36 earnings per share for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of ANIX. Marshall Wace LLP purchased a new position in shares of Anixa Biosciences in the second quarter worth about $39,000. NewEdge Advisors LLC acquired a new stake in Anixa Biosciences during the second quarter worth about $33,000. Jane Street Group LLC increased its position in Anixa Biosciences by 37.2% during the second quarter. Jane Street Group LLC now owns 41,800 shares of the company's stock worth $138,000 after purchasing an additional 11,340 shares during the last quarter. Benjamin Edwards Inc. acquired a new stake in Anixa Biosciences during the second quarter worth about $37,000. Finally, Vanguard Group Inc. increased its position in Anixa Biosciences by 2.1% during the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company's stock worth $4,694,000 after purchasing an additional 29,436 shares during the last quarter. 29.13% of the stock is owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.